167 related articles for article (PubMed ID: 20367288)
1. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer.
Gridelli C; Rossi A; Bareschino MA; Schettino C; Sacco PC; Maione P
Expert Opin Investig Drugs; 2010 May; 19(5):631-9. PubMed ID: 20367288
[TBL] [Abstract][Full Text] [Related]
2. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer.
Gualberto A; Karp DD
Clin Lung Cancer; 2009 Jul; 10(4):273-80. PubMed ID: 19632947
[TBL] [Abstract][Full Text] [Related]
3. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
Scagliotti GV; Novello S
Cancer Treat Rev; 2012 Jun; 38(4):292-302. PubMed ID: 21907495
[TBL] [Abstract][Full Text] [Related]
4. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
7. Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
Cao H; Dong W; Qu X; Shen H; Xu J; Zhu L; Liu Q; Du J
Sci Rep; 2016 Aug; 6():31072. PubMed ID: 27488947
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
9. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
10. Figitumumab (CP-751,871) for cancer therapy.
Gualberto A
Expert Opin Biol Ther; 2010 Apr; 10(4):575-85. PubMed ID: 20175655
[TBL] [Abstract][Full Text] [Related]
11. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
[TBL] [Abstract][Full Text] [Related]
12. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
Gualberto A; Pollak M
Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933
[TBL] [Abstract][Full Text] [Related]
14. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Sangha R; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
[TBL] [Abstract][Full Text] [Related]
15. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).
Belani CP; Goss G; Blumenschein G
Cancer Treat Rev; 2012 May; 38(3):173-84. PubMed ID: 21715100
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
17. [Targeting insulin-like growth factors in the treatment of cancer].
Moro-Sibilot D; Coudurier M; Lantuejoul S
Rev Mal Respir; 2010 Oct; 27(8):959-63. PubMed ID: 20965410
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for cetuximab in non small cell lung cancer?
Morgensztern D; Govindan R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
[TBL] [Abstract][Full Text] [Related]
19. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]